Department of General, Visceral, and Vascular Surgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Strasse 40, D-06097 Halle (Saale), Germany.
J Clin Endocrinol Metab. 2012 May;97(5):1547-53. doi: 10.1210/jc.2011-2534. Epub 2012 Mar 7.
The clinical relevance of medullary thyroid microcarcinoma, a calcitonin-secreting malignancy, as a valid target for biochemical screening programs has been called into doubt.
This investigation aimed at clarifying the intensity of lymphatic spread and exploring the potential for biochemical cure in medullary thyroid microcarcinoma.
This was a retrospective analysis.
The setting was a tertiary referral center.
Included were 233 patients with hereditary (126 patients) or sporadic (107 patients) medullary thyroid microcarcinoma.
The intervention was compartment-oriented surgery.
Clinical-histopathological variables were stratified by primary tumor diameter (2-mm increments) and biochemical cure.
With incremental tumor diameter, increasingly more patients with medullary thyroid microcarcinoma harbored lymph node metastases: from 6 to 62% of patients (P < 0.001) for hereditary and from 13 to 43% of patients (P = 0.01) for sporadic disease. The corresponding biochemical cure rates declined from 96 to 71% (P = 0.001) and from 85 to 77% (P = 0.01). Distant disease (two instances of lung metastasis and one instance of bone and liver metastasis) was exceptional, affecting 1.3% of patients with medullary thyroid microcarcinoma. Strongest predictors of a patient's failure to achieve normal calcitonin serum levels were positive nodal status (79 vs. 11% in hereditary and 79 vs. 12% in sporadic disease; both P < 0.001) and the number of involved nodes (means of 6.6 vs. 0.3 nodes in hereditary and 8.8 vs. 0.4 nodes in sporadic disease; both P < 0.001).
Sporadic and hereditary medullary thyroid microcarcinoma carry a significant risk of lymph node metastasis and postoperative calcitonin elevation.
降钙素分泌性恶性肿瘤——甲状腺髓样微癌的临床相关性已受到质疑,其作为生化筛选计划的有效目标。
本研究旨在阐明淋巴扩散的强度,并探讨甲状腺髓样微癌实现生化治愈的潜力。
这是一项回顾性分析。
三级转诊中心。
纳入了 233 例遗传性(126 例)或散发性(107 例)甲状腺髓样微癌患者。
采用分区定向手术。
临床病理变量按原发肿瘤直径(每 2mm 递增)和生化治愈分层。
随着肿瘤直径的增加,患有甲状腺髓样微癌的患者出现淋巴结转移的比例越来越高:遗传性疾病从 6%到 62%(P < 0.001),散发性疾病从 13%到 43%(P = 0.01)。相应的生化治愈率从 96%降至 71%(P = 0.001)和 85%降至 77%(P = 0.01)。远处疾病(两例肺转移,一例骨和肝转移)罕见,影响 1.3%的甲状腺髓样微癌患者。导致患者降钙素血清水平未恢复正常的最强预测因素是淋巴结阳性状态(遗传性疾病中分别为 79%和 11%,散发性疾病中分别为 79%和 12%;均 P < 0.001)和受累淋巴结数量(遗传性疾病中分别为 6.6 和 0.3 个节点,散发性疾病中分别为 8.8 和 0.4 个节点;均 P < 0.001)。
散发性和遗传性甲状腺髓样微癌存在淋巴结转移和术后降钙素升高的显著风险。